| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Vasicine HCl targets bacterial cells and acts as a bacterial inhibitor. It activates the PI3K/Akt signaling pathway, which is involved in cell survival and proliferation. Its mechanism also involves relaxing bronchial smooth muscles, which is beneficial for respiratory conditions. The compound has demonstrated anti-inflammatory activity in vivo and antimicrobial activity against Gram-positive bacteria.
|
|---|---|
| ln Vitro |
In vitro, Vasicine HCl is characterized as a bacterial inhibitor. It activates the PI3K/Akt signaling pathway and demonstrates significant antioxidant and anti-inflammatory properties. Research suggests additional antimicrobial and antioxidant effects. It inhibits the growth of Gram-positive bacteria including Staphylococcus aureus and Clostridium perfringens.
|
| ln Vivo |
In vivo, Vasicine HCl has been shown to have anti-inflammatory activity in rats with carrageenan-induced paw edema. It is traditionally used to manage respiratory conditions. Its ability to relax bronchial smooth muscles and aid in mucus clearance makes it a valuable compound for respiratory health research. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic profile.
|
| Enzyme Assay |
In vitro bacterial inhibition assays for Vasicine HCl involve determining the minimum inhibitory concentration (MIC) against various bacterial strains. The compound is added to bacterial cultures at different concentrations, and growth is monitored by optical density. Its anti-inflammatory activity can be assessed by measuring its ability to inhibit pro-inflammatory cytokine production in immune cells.
|
| Cell Assay |
For in vitro cell-based assays, immune cells or epithelial cells are cultured and treated with Vasicine HCl at various concentrations. Its effects on cell signaling pathways, such as PI3K/Akt, are analyzed by Western blot. Cell viability is assessed by MTT assays. Its antioxidant activity can be measured by assessing its ability to scavenge free radicals in cell cultures.
|
| Animal Protocol |
In vivo animal studies with Vasicine HCl are conducted in models of inflammation and respiratory conditions. The compound is administered orally or intraperitoneally. Anti-inflammatory activity is assessed in models such as carrageenan-induced paw edema, where paw volume is measured. Its effects on respiratory function can be assessed in models of asthma or bronchitis.
|
| ADME/Pharmacokinetics |
Vasicine HCl (CAS: 7174-27-8) has a molecular weight of 188.23 g/mol and a molecular formula of C11H12N2O·HCl. Appearance: White to off-white solid powder. Melting point: 206-208ºC. Solubility: DMSO: ≥125 mg/mL; H2O: ~50 mg/mL. Storage: Powder -20°C 3 years, 4°C 2 years.
|
| Toxicity/Toxicokinetics |
Vasicine HCl is a research compound and is not approved for human therapeutic use. In preclinical studies, it has shown a manageable safety profile. As a natural alkaloid, it is generally well-tolerated at pharmacological doses. Standard laboratory safety precautions should be followed when handling the compound. Comprehensive toxicology studies would be required for therapeutic development.
|
| References |
[1]. Antimicrobial, antioxidant, and cytotoxic properties of vasicine acetate synthesized from vasicine isolated from Adhatoda vasica L. Biomed Res Int. 2015;2015:727304.
|
| Additional Infomation |
Vasicine HCl (Peganine hydrochloride) is a naturally occurring quinazoline alkaloid isolated from Justicia adhatoda. It is a bacterial inhibitor that activates the PI3K/Akt signaling pathway and demonstrates antioxidant and anti-inflammatory properties. It is traditionally used for respiratory conditions. It is not FDA-approved and is intended for research use only.
|
| Molecular Formula |
C11H12N2O
|
|---|---|
| Molecular Weight |
188.2258
|
| Exact Mass |
224.072
|
| CAS # |
7174-27-8
|
| Related CAS # |
(±)-Vasicine;6159-56-4;Vasicine;6159-55-3
|
| PubChem CID |
197084
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
373.8ºC at 760 mmHg
|
| Melting Point |
206-208ºC
|
| Flash Point |
179.9ºC
|
| LogP |
1.472
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
264
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O([H])[C@]1([H])C2=NC3=C([H])C([H])=C([H])C([H])=C3C([H])([H])N2C([H])([H])C1([H])[H]
|
| InChi Key |
CSDQSAHJCAKJPT-PPHPATTJSA-N
|
| InChi Code |
InChI=1S/C11H12N2O.ClH/c14-10-5-6-13-7-8-3-1-2-4-9(8)12-11(10)13;/h1-4,10,14H,5-7H2;1H/t10-;/m0./s1
|
| Chemical Name |
(3S)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-3-ol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~556.32 mM)
H2O : ~50 mg/mL (~222.53 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.17 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (222.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3126 mL | 26.5632 mL | 53.1265 mL | |
| 5 mM | 1.0625 mL | 5.3126 mL | 10.6253 mL | |
| 10 mM | 0.5313 mL | 2.6563 mL | 5.3126 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
